{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:57:04Z","timestamp":1792173424901,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T00:00:00Z","timestamp":1461801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Dartrix","award":["278580"],"award-info":[{"award-number":["278580"]}]},{"name":"the University College Hospital\/University College London"},{"DOI":"10.13039\/100014461","name":"Biomedical Research Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015873","name":"National Brain Appeal","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015873","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.clon.2016.04.042","type":"journal-article","created":{"date-parts":[[2016,5,8]],"date-time":"2016-05-08T14:40:38Z","timestamp":1462718438000},"page":"622-626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Ipilimumab and Bevacizumab in Glioblastoma"],"prefix":"10.1016","volume":"28","author":[{"given":"T.","family":"Carter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cohn-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Chester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2016.04.042_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2016.04.042_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2016.04.042_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2016.04.042_bib4","first-page":"736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"56","author":"Schadendorf","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.04.042_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clon.2016.04.042_bib6","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clon.2016.04.042_bib7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1212\/01.wnl.0000304121.57857.38","article-title":"Bevacizumab for recurrent malignant gliomas. Efficacy, toxicity, and patterns of recurrence","volume":"70","author":"Norden","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.clon.2016.04.042_bib8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A\u00a0randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2016.04.042_bib9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2016.04.042_bib10","doi-asserted-by":"crossref","first-page":"e29030","DOI":"10.4161\/onci.29030","article-title":"Trial watch: immunostimulatory cytokines in cancer therapy","volume":"3","author":"Vacchelli","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clon.2016.04.042_bib11","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.04.042_bib12","series-title":"Ipilimumab for recurrent glioblastoma: a single-institution case series","author":"Hu","year":"2014"},{"key":"10.1016\/j.clon.2016.04.042_bib13","doi-asserted-by":"crossref","first-page":"v90","DOI":"10.1093\/neuonc\/nou255.50","article-title":"Ipilimumab for recurrent glioblastoma (GBM)","volume":"16","author":"Schaff","year":"2014","journal-title":"Neuro-oncology"},{"issue":"1","key":"10.1016\/j.clon.2016.04.042_bib14","first-page":"1","article-title":"Immune effects of bevacizumab: killing two birds with one stone","volume":"8","author":"Elamin","year":"2014","journal-title":"Cancer Microenvironment"},{"key":"10.1016\/j.clon.2016.04.042_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4049\/jimmunol.194.Supp.213.10","article-title":"Immune checkpoint blockade activates effective anti-tumor immunity in an orthotopic model of glioblastoma (VAC12P.1119)","volume":"194","author":"Klein","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clon.2016.04.042_bib16","first-page":"v116","article-title":"Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy","volume":"16","author":"Reardon","year":"2014","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.clon.2016.04.042_bib17","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1158\/1078-0432.CCR-06-2070","article-title":"Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function","volume":"13","author":"Fecci","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2016.04.042_bib18","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1084\/jem.20130678","article-title":"Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell\u2013mediated glioma rejection","volume":"210","author":"Vom Berg","year":"2013","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clon.2016.04.042_bib19","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","article-title":"Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors","volume":"20","author":"Wainwright","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2016.04.042_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2016.04.042_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2016.04.042_bib22","doi-asserted-by":"crossref","first-page":"TPS2101","DOI":"10.1200\/jco.2014.32.15_suppl.tps2101","article-title":"Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM)","volume":"32","author":"Sampson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.04.042_bib23","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2016.04.042_bib24","series-title":"Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis","author":"Brahmer","year":"2014"},{"issue":"19","key":"10.1016\/j.clon.2016.04.042_bib25","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.clon.2016.04.042_bib26","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2016.04.042_bib27","series-title":"Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab","author":"NICE","year":"2015"},{"key":"10.1016\/j.clon.2016.04.042_bib28","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The evolving role of immune checkpoint inhibitors in cancer treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.clon.2016.04.042_bib29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd4476","article-title":"The immune checkpoint inhibitors: where are we now?","volume":"13","author":"Webster","year":"2014","journal-title":"Nat Rev Drug Disc"},{"key":"10.1016\/j.clon.2016.04.042_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semradonc.2014.07.004","article-title":"Combination of radiotherapy and immune checkpoint inhibitors","volume":"25","author":"Pilones","year":"2015","journal-title":"Semin Radiat Oncol"},{"issue":"7","key":"10.1016\/j.clon.2016.04.042_bib31","doi-asserted-by":"crossref","first-page":"e101764","DOI":"10.1371\/journal.pone.0101764","article-title":"Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model","volume":"9","author":"Belcaid","year":"2014","journal-title":"PloS one"},{"key":"10.1016\/j.clon.2016.04.042_bib32","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655516300760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655516300760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:42:11Z","timestamp":1760542931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655516300760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0936655516300760"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2016.04.042","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ipilimumab and Bevacizumab in Glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2016.04.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}